Pharmaceutical companies claim they need to charge high
prices to fund their research and development. This just isn’t so. For one
thing, drug companies spend more on marketing and advertising than on new
ideas. Pharmaceutical companies spend 11% of their income on R & D and 40 %
of their income promoting their brand.
As it is, most of the important innovations come out of universities
and research centers, like the National Institutes of Health, funded by
government and foundations.
A secretive group met behind closed doors in New York this
week. What they decided may lead to higher drug prices for hundreds of millions
around the world. Representatives from the United States and 11 other Pacific
Rim countries convened to decide the future of their trade relations in the
so-called Trans-Pacific Partnership (T.P.P.). Powerful companies appear to have
been given influence over the proceedings, even as full access is withheld from
many government officials from the partnership countries.
Among the topics negotiators have considered are some of the
most contentious T.P.P. provisions — those relating to intellectual property
rights. And we’re not talking just about music downloads and pirated DVDs.
These rules could help big pharmaceutical companies maintain or increase their
monopoly profits on brand-name drugs. Overly restrictive intellectual property
rights actually slow new discoveries, by making it more difficult for
scientists to build on the research of others and by choking off the exchange
of ideas that is critical to innovation.
Big Pharma boasts the largest lobbying group in Washington,
and is pulling the puppet strings of far too many government officials. The
whole world pays the real price in the form of worse health and unnecessary
deaths.
No comments:
Post a Comment